The non-receptor tyrosine kinase Fyn-related kinase (FRK) has been reported to affect cell proliferation in several cancer types. However, its effect on the proliferation of clear cell renal cell carcinoma (ccRCC) remains largely unknown. Purpose: The objective of this study was to investigate the expression pattern and function of FRK in ccRCC. We further determined how FRK interacted with other molecules to regulate ccRCC proliferation.
Introduction
Renal cell carcinoma (RCC) is the second most common cancer in the urological system and accounts for ~3% of malignant neoplasms worldwide. 1 More than 90% of kidney tumors are renal cell carcinomas (RCCs), which arise from the epithelial lining of the proximal convoluted tubule. 2 Clear cell renal cell carcinoma (ccRCC) is the most common (70%-80%) and most aggressive histological subtype of RCC.
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Jing et al miRNAs are small noncoding RNAs (19-22 nt) , known to negatively regulate their target genes through direct binding with the 3′-untranslated regions (UTRs) of target mRNAs. 5, 6 Increasing studies revealed that miRNAs were implicated in the development and progression of RCC. [7] [8] [9] miR-19a and miR-19b, two key oncogenic components of the miR-17~92 cluster, belong to the same miRNA family (miR-19). They differ in only one nucleotide outside of the seed sequence and are therefore likely to target the same mRNAs. 10 Although miR-19 plays an oncogenic role in multiple malignancies, [11] [12] [13] its role in ccRCC remains largely unknown. To date, only a few target genes have been validated. 14, 15 Additional studies are necessary to identify more target genes of miR-19 and thereby elucidate the functions of miR-19 in ccRCC.
FRK, also known as protein tyrosine kinase 5, was originally discovered in breast cancer cells. 16 FRK was initially characterized as a tumor suppressor that arrested cell growth and suppressed tumorigenesis; [17] [18] [19] [20] however, recent studies indicated that FRK contributed to the progression of several malignancies as well.
21, 22 These contradictory results suggest that the function of FRK is cell-and tissue-type specific. Thus far, the expression and function of FRK in ccRCC remain unclear, and how FRK is regulated in ccRCC requires further investigation.
Here, we investigated the expression of FRK in ccRCC and determined its impact on cell proliferation. We further identified and validated miR-19 as a novel regulator of FRK and revealed how miR-19 interacted with the FRK-PTEN axis to modulate renal cancer cell proliferation.
Materials and methods cell culture and transfection
Human cell lines 293T, HK-2, CAKI-1, ACHN, A498, 769P, 786-O, and OS-RC-2 were obtained from the Cell Bank of Shanghai Institute of Cell Biology (Chinese Academy of Medical Science, Shanghai, China). 769-P, 786-O, and OS-RC-2 were cultured in RPMI-1640 (HyClone, Logan, UT, USA) supplemented with 10% FBS (HyClone) at 37°C with 5% CO 2 . ACHN and A498 cells were cultured in MEM (HyClone) with 10% FBS. CAKI-1 cells were cultured in McCoy's 5a medium (HyClone) modified with 10% FBS. HK-2 cells were cultured in DMEM/F12 (HyClone) medium with 10% FBS. 293T cells were cultured in DMEM (HyClone) with 10% FBS. Transfection was performed using Lipofectamine 3000 Transfection Reagent (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions.
Tissue specimens
Thirty renal tumor specimens and paired normal renal tissues were collected from patients undergoing radical or partial nephrectomy (laparoscopic or open) in the Urology Department, First Hospital of China Medical University (Shenyang, China) for a renal mass between July 2016 and November 2017. The Ethics Committee of China Medical University approved this study according to the Declaration of Helsinki. Written informed consent was obtained from all individual participants included in the study.
antibodies and reagents
Antibodies used in this study were obtained as follows: anti-FRK (abs133481; Absin, Shanghai, China), anti-PTEN (ab32199; Abcam, Cambridge, MA, USA), anti-GAPDH (5174; Cell Signaling, Danvers, MA, USA).
Western blot analysis
Cells were rinsed with cold PBS and homogenized with RIPA lysis buffer supplemented with 1 nM PMSF (Beyotime, Shanghai, China) and phosphatase inhibitor cocktail (MedChem Express, Shanghai, China). Afterward, 30 μg of whole cell lysates was separated by 4%-20% SDS-PAGE and electrophoretically transferred onto a polyvinylidene fluoride membrane (EMD Millipore, Billerica, MA, USA). The membrane was washed with TBST, blocked with 5% nonfat milk diluted in TBST for 1 hour and then incubated with appropriate primary antibodies overnight at 4°C. The membrane was washed and then incubated with HRPconjugated secondary antibodies for 1 hour at 37°C. Bands were visualized with enhanced chemiluminescence reagents (Transgen Biotechnology, Beijing, China) and scanned using a DNR Microchemi imaging system (DNR Bio-Imaging System, Ltd., Jerusalem, Israel). Protein quantification was conducted using ImageJ software.
rna extraction and real-time quantitative Pcr (qPcr)
Total RNA was extracted using the Eastep Super Total RNA Extraction Kit (Promega Corporation, Fitchburg, WI, USA). miRNA was extracted using the miRcute miRNA Isolation Kit (TIANGEN Biotech, Beijing, China). Total RNA concentrations were determined by measuring the optical density at a wavelength of 260 nm. Then, the first-strand cDNA was synthesized using a reaction mixture containing 500 ng of total RNA, 2 μL 5× PrimeScript RT Master Mix (TaKaRa, Dalian, China), and RNase-free water at a total volume of submit your manuscript | www.dovepress.com
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Jing et al 10 μL. For microRNAs, cDNA was synthesized using the Mir-XTM miRNA First-Strand Synthesis Kit (TaKaRa). qPCR was conducted using SYBR Green PCR Master Mix (TaKaRa) on a LightCycler 480 Real-Time PCR instrument (Hoffman-La Roche Ltd., Basel, Switzerland). The final 25 μL of the reaction mixture contained 12.5 μL TB Green Premix Ex TaqII (2×), 0.4 μM of each primer, and 2 μL cDNA templates. To confirm the specificity of the amplified product, a melting curve analysis was performed. The primers used for target genes were purchased from Sangon Biotech (Shanghai, China). The sequences of primers were as follows (in the 5′-3′ orientation):
FRK forward, 5′-CTCTGGGAGTACCTAGAACCC-3′; FRK reverse, 5′-AGCCTGGTAATCAAACAAAGCC-3′; GAPDH forward, 5′-TGTGGGCATCAATGGA TTTGG-3′;
GAPDH reverse, 5′-ACACCATGTATTCCGG GTCAAT-3′;
hsa-miR-19a-3p forward, 5′-ACACTCCAGCTGG GAGTCAAAACGTATCTAA-3′;
and hsa-miR-19b-3p forward, 5′-ACACTCCAGCTGG GAGTCAAAACGTACCTAA-3′; snRNA U6 and GAPDH were used as internal controls for miRNA and mRNA, respectively. Data are presented as relative quantification based on the calculation of 2 −ΔΔCt .
immunohistochemistry
Specimens that were previously formalin-fixed and paraffinembedded were sliced into 4-μM sections and processed for deparaffinization and then rehydration. Antigen retrieval, suppression of endogenous peroxidase activity, and 10% BSA blocking were performed before primary antibody incubation. FRK antibodies were used as primary antibodies for overnight incubation at 4°C. The slides were subsequently incubated with peroxidase-conjugated secondary antibody (ZSGB Bio, Beijing, China) for 90 min, and a solution of the peroxidase-labeled polymer, 2,4-diaminobutyric acid, was used for signal development for 1 minute. The sections were counterstained with hematoxylin followed by dehydrating and mounting.
cell proliferation assays
The effects of FRK on cell proliferation were measured by CCK-8, 5-ethynyl-2′-deoxyuridine (EdU) incorporation, and colony formation assays. ACHN, CAKI-1, and 786-O cells were used in the CCK-8 assays, and 2,000 cells were seeded in 96-well plates containing 100 μL of medium per well and incubated at 37°C. Ten microliters of CCK-8 reagent (Dojindo, Tokyo, Japan) was added and coincubated for 1 hour at the indicated time points. The absorbance value at a wavelength of 450 nm, which was proportional to the total number of cells per well, was then measured with a microplate reader (Model 680; Bio-Rad laboratories, Hercules, CA, USA). The results represent the average of three independent replicates. For EdU incorporation assays, EdU (10 mM; RiboBio, Guangzhou, China) was added to the culture medium and incubated for 4 hours. The 786-O cells were then fixed and stained with Hoechst 33342. EdU-positive cells (proliferating cells) were observed and counted in five randomly selected fields under a fluorescence microscope. The ratio of the number of EdU-positive cells per field to the number of Hoechst 33343-positive cells in the same field was used to quantify the cell proliferation. For the colony formation assay, four hundred 786-O cells per well were plated on six-well plates, and 10 days after seeding, cell colonies were stained with 0.5% crystal violet solution and counted.
Phos-tag analysis
The proteins were separated on 10% SDS-polyacrylamide gels prepared with 20 μM phosbind acrylamide (APExBIO, F4002) and 40 μM ZnCl 2 . Gels were electrophoresed at 120 V for 1 hour. Prior to transfer, the gels were first equilibrated in transfer buffer containing 5 mM EDTA for 10 minutes three times and then in transfer buffer without EDTA for 10 minutes. Protein transfer from the phos-tag acrylamide gel to the PVDF membrane was performed for 2 hours at 350 mA, and then the blot was probed with the anti-PTEN antibody.
luciferase assay
Reporter constructs containing the 3′-UTR of FRK were cloned into the pGL3-control vector. 293T cells were transiently transfected with the 3′-UTR reporter constructs (2 μg/well in six-well plates) and 10 nmol/L of the miR19a/b-3p mimics (GenePharma, Shanghai, China) using Lipofectamine 3000 Transfection Reagent (Thermo Fisher Scientific). The activity of the 3′-UTR reporter constructs was normalized to the Renilla luciferase activity. After incubation for 48 hours, the cells were lysed with passive lysis buffer (Promega Corporation), and their activity was assessed using a Dual-Luciferase Assay Kit (Promega Corporation) according to the manufacturer's protocol.
statistical analysis
The results are presented as the means ± standard deviation. Where appropriate, two-sample t-tests and ANOVA were submit your manuscript | www.dovepress.com
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Jing et al used. Correlations were calculated according to Pearson correlation. All tests were performed using GraphPad Prism 7 Software (GraphPad Software, Inc., La Jolla, CA, USA), and P,0.05 was considered significant. All experiments were performed at least three times.
Results
reduced FrK expression was detected in ccrcc and predicted poor survival for ccrcc patients
The expression of FRK in ccRCC and paired normal renal tissues was determined using qPCR, immunoblotting, and IHC. qPCR showed that the expression of FRK mRNA was lower in ccRCC tissues than in normal renal tissues ( Figure 1A) . The results from immunoblot analysis also indicated that FRK protein expression was lower in ccRCC ( Figure 1B and C) . For the immunohistochemistry, strong staining for FRK was detected in the cytoplasm of renal tubular epithelium, while in ccRCC tissues, only weak staining was detected in the cytoplasm of cancer cells ( Figure 1D) . Analysis of the TCGA KIRC data set showed that the FRK transcript level was lower in ccRCC than in normal renal tissues ( Figure S1A-C) . 23 In addition, the analysis based on TCGA KIRC data sets indicated that low 
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Jing et al FRK expression in the ccRCC predicted poor overall survival for ccRCC patients ( Figure 1E) .
The endogenous expression of FRK in 293T and HK-2 kidney cells and different renal cancer cell lines was also determined by qPCR and immunoblot analyses. The results showed that the expression of FRK was lower in renal cancer cell lines than that in HK-2 kidney cells and 293T cells at both the mRNA and protein levels ( Figure 1F-H) .
FrK inhibited the proliferation of ccrcc via PTen
The effect of FRK on the proliferation of renal cancer cell lines was determined using CCK-8, EdU incorporation, and colony formation assays. The CCK-8 results revealed that FRK knockdown promoted the growth of ACNH, CAIK-1, and 786-O cells, whereas FRK overexpression markedly reduced the growth of renal cancer cells compared with control cells (Figure 2A-C Figures 3A and S3A ). In addition, FRK overexpression promoted the phosphorylation of PTEN (Figures 3B and S3B ).
Since PTEN is also a critical regulator of cell proliferation and cell cycle progression, 24, 25 to determine whether PTEN is involved in the growth inhibitory effect of FRK on renal cancer cells, si-PTEN was used in addition to FRK overexpression vectors in CCK-8 and EdU incorporation assays ( Figures 3D and E and S3C and D) . The results showed that FRK-induced growth suppression can be alleviated by PTEN interference, suggesting that PTEN plays a role in FRK-mediated growth suppression in renal cancer cells. 
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miR-19 was identified and validated as a direct regulator of FrK
Over the past decade, an increasing number of studies have shown that miRNAs are involved in RCC development and progression. FRK downregulation could also be a result of dysregulated miRNAs in ccRCC. Thus, we searched starBase (http://starbase.sysu.edu.cn/index.php) for predicted miRNAs that potentially targeted FRK for inhibition. 26, 27 Several features of the top-ranked miRNA, miR-19a/b3p, attracted our attention. miR-19a/b-3p was not only upregulated in ccRCC but also inversely correlated with FRK expression (Figure S2A and B) . In addition, data from TCGA KIRC showed that high expression of miR-19a-3p and miR-19b-3p in ccRCC predicted poor survival in ccRCC patients ( Figure S2C ). Furthermore, PTEN was a common downstream effector shared by both miR-19 and FRK. These findings suggested that miR-19 may play a role in ccRCC proliferation by interacting with FRK and PTEN.
To broaden our knowledge of miR-19 in ccRCC, we first examined the expression of miR-19a-3p and miR-19b-3p in ccRCC specimens. The qPCR results showed that the expression of both miR-19a-3p and miR-19b-3p was higher in ccRCC tissues than in normal renal tissues ( Figure 4A and B). Furthermore, the expression of miR-19a-3p and miR19b-3p was inversely correlated with FRK mRNA expression in ccRCC ( Figure 4C and D) which was consistent with the findings from the KIRC database. Since miR-19a-3p and miR-19b-3p belong to the same miRNA cluster, it is unsurprising that they show a similar pattern in the expression and correlation with FRK.
To confirm that FRK was regulated by miR-19a/b-3p, qPCR, immunoblot, and luciferase reporter assays were also employed. (Figure S4A-C) . In the luciferase reporter assay, we observed a significant downregulation of luciferase activity upon cotransfection of miR-19a/b3p mimics and wild-type FRK 3′-UTR compared to the control group ( Figure 4K ). However, cotransfection of miR-19a/b-3p mimics and plasmids with a mutation in the predicted binding site did not result in a reduction of luciferase activity. These findings indicated a direct regulation of FRK by miR-19a/b-3p through binding to the 3′-UTR of the FRK mRNA.
mir-19 regulated the proliferation of ccrcc by targeting FrK-PTen
The effect of miR-19a-3p and miR-19b-3p on the proliferation of renal cancer cells was also determined. The results from CCK-8 revealed that both miR-19a-3p and miR19b-3p mimics enhanced the proliferation of ACHN cells in comparison with control groups, whereas miR-19a-3p and miR-19b-3p inhibitors suppressed the proliferation of ACHN cells ( Figure 5A and B) . In EdU incorporation assays, more EdU positively stained cells were observed in ACHN cells transfected with miR-19a/b-3p mimics compared with the control group, while transfection of miR-19a/b-3p inhibitors reduced the percentage of EdU-positive cells ( Figure 5C and D).
Since miR-19a-3p and miR-19b-3p differ in only one nucleotide outside the seed sequence, it can be expected that they share the same target mRNAs and produce similar effects on cell proliferation. Hence, only a miR-19b-3p inhibitor was employed in the following experiments. To determine whether the growth inhibitory effect of miR-19 was mediated via the FRK-PTEN axis, si-FRK and si-PTEN were used in addition to miR-19b-3p inhibitors in CCK-8 and EdU assays. Although transfection of the miR-19b-3p inhibitor suppressed the growth of ACHN cells, this suppression could be partially rescued by FRK or PTEN 
Discussion
This study found that FRK expression was reduced in ccRCC compared to normal renal tissues and that FRK functioned as a tumor suppressor in renal cancer cells by inhibiting cell proliferation. Furthermore, FRK was negatively regulated by miR-19a-3p and miR-19b-3p, and the expression of these miRNAs was upregulated in ccRCC.
We also found that miR-19a-3p and miR-19b-3p could promote the proliferation of renal cancer cells by targeting the FRK-PTEN axis.
Earlier studies have attributed a tumor suppressive role to FRK due to its growth inhibitory effect in breast and glial cancers. 17, 18 However, recent studies indicate that FRK contributes to tumor progression in several malignancies. 21, 22, 28 These contradictory results suggest that the function of FRK is cell-and tissue-type specific and must be determined through a case-by-case approach. To the best of our knowledge, this study is the first to provide evidence of reduced FRK expression in ccRCC and its role in suppressing cell proliferation by targeting PTEN. However, the role of FRK in apoptosis, migration, and other biological processes is still unclear and awaits further investigation. In addition, studies aimed at identifying and characterizing more substrates and binding partners of FRK will be necessary to improve our understanding of FRK.
The miR-17~92 cluster, which includes six mature miRNAs (miR-17, miR-18a, miR-19a, miR-19b, miR-20a, and miR-92a), is believed to be the first miRNA cluster with oncogenic potentials. 29 Chow et al was the first to report the upregulation of miR-19~92 in ccRCC and found the growth promoting effect of two members of this cluster (miR-17-5p and miR-20a). 30 Recent studies found that miR-19 plays an oncogenic role by targeting PIK3CA and RhoB in ccRCC. 14, 15 Here, we identified FRK as a novel downstream effector of miR-19a-3p and miR-19b-3p, expanding the target gene spectrum of miR-19. Notably, PTEN was reported to be a direct target of both miR-19 and FRK in previous studies. 19, 31, 32 The discovery of a regulatory relationship between miR-19a/b-3p and FRK in the present study added to the complexity of this regulatory network. Furthermore, the pleiotropic nature of miRNAs dictates that miR-19 may be involved in more cellular processes in addition to cell proliferation. Additional studies are needed to identify target mRNAs regulated by miR-19, and thus elucidate the role of miR-19 in ccRCC. The diagnostic and prognostic values of miR-19 should also be explored in the future since the prognostic data from the TCGA KIRC indicate that high miR-19 expression is associated with poor survival for ccRCC patients. In addition, as ccRCC is resistant to conventional chemotherapy and radiotherapy, treatments targeting miR-19 can be considered in therapeutic strategies for ccRCC patients.
Conclusion
Collectively, our study identified FRK as a novel regulator of proliferation that was targeted by miR-19a-3p and miR19b-3p. miR-19a/b-3p promotes the proliferation of ccRCC by targeting the FRK-PTEN axis ( Figure 5H ). These findings unravel a new mechanism involved in ccRCC proliferation regulation and may be useful in the identification of novel therapeutic targets for ccRCC. 
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